clinical trials for glp-1 obesity meds actively recruiting Amycretin — a novel treatment that targets both and amylin receptors — has shown early success in phase 1 testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD Optimizing GLP-1 therapies for obesity

Local recurrence is common when margins are positive (R1/R2)

GLP-1s like Ozempic or dual-action options like Mounjaro arent overnight fixes

Elevated histone expression promotes life span extension

Gut microbial -glucuronidases regulate host luminal proteases and are depleted in irritable bowel syndrome

Although a 2-week treatment seems to be rather short for improving a hard endpoint like hepatic fibrosis, mechanistically, these beneficial effects of liraglutide were attributed, at least in part, to its ability to inhibit the activation of the receptor for the advanced glycation end products (RAGE)/nicotinamide adenine dinucleotide phosphate (NADPH) oxidase signaling pathway, which is involved in the formation of reactive oxygen species (ROS), a finding also confirmed in in vitro experiments in the same study [27]